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ABSTRACT Toll-like receptors (TLRs) are major components of the innate immune system that recognize the conserved 
molecular structures of pathogens (pathogen-associated molecular patterns; PAMPs). TLRs are found in many dif-
ferent cell types, ranging from epithelial to immunocompetent cells. TLR binding triggers the expression of several 
adapter proteins and downstream kinases, leading to the induction of key pro-inflammatory mediators. This results 
in the activation of both the innate immune response (elevated expression of antiapoptotic proteins, proinflamma-
tory cytokines, and antibacterial proteins), as well as the adaptive immune response (maturation of the dendritic cells, 
antigen presentation, etc.). In consequence of their ability to enhance the specific and nonspecific immune reactions 
of an organism, TLR agonists are widely used in the therapy of infectious diseases and, as adjuvants, in the therapy 
of malignant neoplasia. However, to date, TLRs have had the opposite effects on tumor progression. On the one hand, 
TLR ligands can suppress tumor growth. On the other hand, TLR agonists can promote the survival of malignant cells 
and increase their resistance to chemotherapy. The purpose of this review is to summarize the available data on the 
effects of TLRs and their agonists on tumor progression, as well as the mechanisms underlying the differences in the 
effects of TLRs on tumor growth.
KEYWORDS toll-like receptors, agonists of innate immune receptors, tumor progression, innate immune response, 
inflammation
ABBREVIATIONS TLR – toll-like receptor, LPS – lipopolysaccharide, NF-kB – nuclear transcription factor kB, PRR – 
pattern recognition receptor, PAMP – pathogen-associated molecular pattern, DAMP – damage-associated molecular 
pattern, IRF – interferon regulatory factor, ss- and dsRNA – single-stranded and double-stranded ribonucleic acid, 
TNF-α – tumor necrosis factor α, IL – interleukin, IFN – interferon, NK-cells – natural killers, siRNA – small interfer-
ing RNA, TGF – transforming growth factor
INTRODUCTION
According to the modern concept, inflammation is one 
of the main causes behind the appearance and progres-
sion of a tumor [1, 2]. The causative mechanism of this 
phenomenon is not well understood, although some key 
events at the site of the inflammation, required for the 
appearance and progression of a tumor, are known.
1) The cells localized on the site of the inflammation 
sustain a high activity of the transcription factor NF-kB 
[3], which is responsible for the expression of anti-inflam-
matory cytokines, many of them (GROα,β,γ, IL-8, MIP-
3α) exhibiting a tumor-stimulating action [4, 5]. Moreo-
ver, NF-kB is regarded as a major antiapoptotic factor, 
as it activates the expression of a series of genes that en -
code antiapoptotic proteins, such as IAP, Bcl-2, Bcl-X, 
etc. These proteins elevate the cells’ resistance to various 
stress agents associated with inflammation [6, 7].
2) An inflammation is accompanied by the induc-
tion of the oxidative stress that causes the appearance 
and accumulation of mutations and genome rearrange-
ments in cells [8].
3) Many anti-inflammatory cytokines (GROα/CXCL1, 
GROβ/CXCL2, GROγ/CXCL3, IL-8/CXCL8, MIP-3a, 
and IL-1) and growth factors (TGF-β1, PDGF, bFGF, 
TGF-α, IGF-I, IGF-II) that enhance the migration of 
stromal (fibroblasts) and epithelial cells, followed by their 
proliferation, are secreted at late stages of an inflamma-
tion [9]. In a chronic inflammation, processes of reparation 
and alteration often occur simultaneously, which enforc-
es the cells to proliferate under hypoxia and genotoxic 
stress conditions, thus increasing the risk of mutations.
The most common and well-studied cause of inflam-
mation is microbial invasion; the process by which the 
pathogen can affect, in one way or another, the host 
cell’s homeostasis.
One of these mechanisms is the interaction of the 
pathogen’s highly conserved molecular domains with 
pattern-recognizing receptors (PRR – RIG-I-like re-
ceptors, Nod-like receptors, C-type lectins, Toll-like 
receptors (TLRs), etc.) localized on the surface or intra-
cellular membranes of eukaryotic cells [10].
Thanks to their capability to bind with various bacte-
rial ligands, PRRs play a crucial role in the development 
of an inflammation, by initiating the development of the 
innate immune response through increasing the expres-
sion of some antiapoptotic proteins, anti-inflammatory 
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cytokines, and antibacterial proteins. They also stimulate 
the acquired immune response by inducing the matura-
tion of dendrocytes, presentation of the captured anti-
gen, and differentiation of naive T-helpers [11].
Therefore, studies focusing on the role of PRRs in 
the induction of tumorigenesis and stimulation of tu-
mor progression in the course of bacterial infection are 
a pressing priority.
In this review, we focused our attention on the role 
of ТLRs in the development of inflammatory processes 
and attempted to gauge their interrelationship with tu-
mor progression.
The data accumulated to date suggest an association 
between ТLRs and tumor growth. However, these data 
are contradictory; both the tumor-stimulating [12, 13] 
and tumor-suppressing [14, 15] effects of TRLs have 
been reported.
As such, we have sought to summarize the available 
data and brood over the possible mechanisms that un-
derpin the variations in the observed effects of TLRs 
on tumor growth.
THE ROLE OF ТLRs
ТLRs function as members of the PRR family that me-
diates specific recognition of conserved Pathogen-As-
sociated Molecular Patterns (PAMPs). TLRs activate 
the innate immune system by binding with РАМР 
and largely determine the development of the adap-
tive immune response [16, 17]. The most conserved role 
of ТLRs is the activation of the antimicrobial immune 
response in both the skin and mucosa of respiratory, 
gastrointestinal, and urogenital tracts.
ТLRs recognize microbial molecules, which results 
in the development of inflammatory reactions caused 
by the activation of the NF-kB regulating expression of 
anti-inflammatory cytokines (TNF-α, IL-1, IL-6, etc.) 
and chemokines (MCP-1, MCP-3, GM-CSF, etc.).
TLRs have been implicated in the transcriptional and 
posttranslational regulation (proteolytic cleavage and 
secretion) of antimicrobial factors, such as defensins 
α and β, phospholipase A2, lysozyme, and so on. [18]. 
TLRs intensify the phagocytosis of microorganisms and 
optimize their inactivation by regulating the release of 
peroxy radicals and nitric oxide [19, 20].
It is known that TLRs localized on the surface of en-
dothelial cells indirectly support the migration of leu-
cocytes into the inflammation focus by stimulating the 
expression of leucocyte adhesion molecules E-selectin 
and ICAM-1 [21].
The TLR stimulation directly leads to the elevation 
of interferon (IFN)-α/β production by both stromal and 
hematopoietic cells, which is important for the organ-
ism to defend itself against certain viral and bacterial 
infections [22]. Moreover, as was recently discovered, 
TLRs – via the activation of a series of factors, such as 
FADD, caspase 8, and protein kinase R (PKR) or the 
stimulation of IFN-α/β expression – can induce the 
development of apoptosis, an important mechanism of 
tissue protection against microbial pathogens [23].
TLRs play a crucial role in the regulation of the 
adaptive immune response. In particular, the TLR-
dependent activation of professional antigen-present-
ing dendritic cells is determinative in several essential 
processes providing the development of the adaptive 
immune response, such as the activation of mature T-
cells, processing and presentation of microbial antigens, 
elevation of the expression of the costimulatory mole-
cules (СD80, CD86) required for the activation of naive 
CD4+-T-cells, and suppression of regulatory T-cells via 
IL-6 production [24]. The TLR-dependent activation is 
also important for B-cell proliferation and maturation 
during the infection process [25].
Thus, ТLRs play an important role in initiating the 
development of the inflammatory process (activation of 
innate immune reactions) in response to the introduc-
tion of various pathogens (including protozoa, fungi, 
bacteria, and viruses). Moreover, according to the mod-
ern view, pathogen recognition by TLRs is the midpoint REVIEWS
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Table 1. Activation of the transcription factors NF-κB and 
IRF by different TLRs.
TLR type Activation of 
NF-κB Activation of IRF
TLR2/1/6
TLR3
TLR4
TLR5
TLR7
TLR8
TLR9
+
+
+
+
+
+
+
-
+ (IRF3)
+ (IRF3)
-
+ (IRF5, 7)
+(IRF5, 7)
+(IRF5, 7)
in the development of the adaptive immune response, 
which is the second line of defense [11]. TLRs also par-
ticipate in the functioning of the normal gastrointes-
tinal system and are implicated in the pathogenesis of 
autoimmune diseases (systemic lupus erythematosus), 
arthritis, atherosclerosis, and certain other disorders 
[26, 27]. Recent data indicate that TLRs can either ac-
tivate antitumor immunity [28, 29] or, on the contrary, 
stimulate tumor progression [30, 31].
TLR STRUCTURE, EXPRESSION IN DIFFERENT 
CELL TYPES, AND SPECIFICITY TO VARIOUS 
MOLECULAR STRUCTURES (PAMP AND DAMP)
Based on their structure, TLRs are members of the 
family of IL-1 receptors (IL-1R). They are transmem-
brane proteins that are expressed on the cell’s surface 
and in subcellular compartments (particularly endo-
somes). TLR localization depends on the type of the rec-
ognized ligand. For example, the TLRs 1, 2, 4, 5, and 6, 
which bind with structural bacterial components, are 
localized on the cell’s surface, while the TLRs 3, 7, 8, 
and 9, primarily recognizing virus-associated nucleic 
acids (dsRNA, ssRNA, and DNA), are localized in en-
dosomes, where they interact with the ligands that ap-
pear after the deproteination of virions [16].
The TLR’s structure includes the N-terminal leu-
cine-rich repeat (LRR) responsible for ligand binding, 
one transmembrane domain, and the C-terminal cy-
tosolic signaling domain (homologous to the intracel-
lular domain of IL-1R) [32].
TLRs are expressed in most types of cells in the 
human body, including non-hematopoietic epithelial 
and endothelial cells. The number of simultaneously 
expressed ТLRs and their combination are specific for 
each cell type; the largest number is observed in cells 
of hematopoietic origin, such as macrophages, neu-
trophils, and dendritic cells (Table 1) [33].
To date, 13 different TLRs have been identified in 
mammals: 10 in humans and 12 in mice. The TLRs 1 
through 9 are conserved in humans and mice; howev-
er, some difference exists. The gene encoding TLR10 
is only found in humans, whereas the TLR11 gene is 
present in both species, but possesses functionality in 
mouse only [34].
The hallmark of TLRs that distinguishes them from 
the receptors of acquired immunity (T- and B-cell re-
ceptors) is their capability to recognize not just unique 
epitopes, but also the evolutionary-conserved patho-
gen-associated molecular patterns (PAMP), which are 
widely distributed in all taxa of microorganisms and 
viruses, regardless of their pathogenicity.
The specificity of PAMP recognition is well studied 
for the majority of TLRs. The ligands of TLR 1–9 and 
11 are now known (Fig. 1). The biological role and the 
specificity of human TLR10 and murine TLR 12 and 
TLR 13 remain unclear [16].
The most common microbial ligands of TLRs are the 
following:
- bacterial lipopeptides, lipoteichoic acid (LTA), and 
peptidoglycans; mycobacterial lipoarabinomannan; and 
zymosan from the fungal cell wall – which bind with 
TLR2 that forms heterodimers with TLR1, TLR6, and 
CD14;
- LPS of Gram-negative bacteria; the TLR4 ligand;
- flagellin, a principal component of bacterial flagella 
that activates TLR5;
- protozoan profilin-like structures binding with 
TLR11;
- DNA (demethylated CpG-islets) recognized by TLR9;
- dsRNA, the TLR3 ligand;
- ssRNA, the TLR7 and the TLR8 ligand.
It was shown recently that TLRs can be activated 
by many endogenous molecules, the so-called alarmins 
(hyaluronic acid, heat shock proteins, etc.), appearing in 
tissue decay. These heterogeneous in their nature and 
structure (PAMP and alarmins) substances recognized 
by TLRs are presently allied to one family called DAMP 
(Damage Associated Molecular Patterns) [35].
SIGNALING CASCADE ACTIVATED FOLLOWING THE 
INTERACTION OF TLRS WITH THEIR OWN LIGANDS
Now, after describing the TLR’s structure and its ac-
tions, we can focus on the processes set in motion after 
their binding with their own ligands.
The binding of a ligand with TLR initiates a cascade of 
signals going back to the plasmatic TIR-domains of TLR. 
The signal from the TIR-domain – via the adapter mol-
ecules MyD88 (myeloid differentiation factor 88), TIRAP 
(TIR domain-containing adapter proteins), TICAM1 
(TRIF), TICAM2 (TIR-containing adaptеr molecule 2) – 
is transmitted to the corresponding kinases (TAK, IKK, 
TBK, MAPK, JNKs, p38, ERK, Akt, etc.) that specifical-
ly activate the transcription factors (NF-kB, AP-1, and 
IRF) responsible for the expression of various anti-in-
flammatory and antimicrobial factors. All TLRs, except 
for TLR3, transmit the signal to kinases using MyD88. 24 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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TLR4/MD-2
ЛПС
TLR1/2
Lipopeptide
Plasma membrane
TRAM MyD88 MyD88
Endosome
Extracellular 
domain
Transmembrane  
domain
TIR-domain
dsRNA
TLR3 TRIF TRAF TAK
RIP
IRF3 NF-kB AP-1
Nucleus
IRF3  NF-kB AP-1
Table 2. TLRs in clinical trials.
Cancer TLR
Non-small cell lung carcinoma, late stage
Melanoma, stage IV
Melanoma, stage IIIb/c or IV
Incompletely re-sectable pancreatic cancer
Recidivism of  non-Hodgkin’s lymphoma
Recidivism of  glioblastoma
Chronic lymphocytic leukemia
TLR9
TLR7
TLR9
TLR2/6
TLR9
TLR9
TLR7
The TLR3 transmits the signal via TICAM1, and TLR4 – 
via both MyD88 and TICAM1 (Fig. 2).
Activation of one or the other factor depends on the 
type of TLR that is transmitting the signal. In particu-
lar, almost all TLRs (TLR2 and its co-receptors TLR1 
and TLR6, as well as TLR4–9 and TLR11) bind with 
their own ligands to activate NF-kB, one of the main 
factors regulating the expression of anti-inflammatory 
cytokines, such as IL-1, -6, -8, etc. Signal transduction 
via TLR3, 4, 7–9 leads to the activation of another fam-
ily of anti-inflammatory transcription factors, IRF. Sig-
nals transmitted via TLR3 or TLR4 lead to the activa-
tion of IRF3, which regulates the expression of IFN-β 
and is regarded as a crucial component of antiviral im-
munity. Signal transduction via TLR7–9 results in the 
activation of IRF-5 and IRF-7, as well as the expression 
of IFN-α, which is of critical importance for the antiviral 
defense. Signaling via TLR2 or TLR5 does not result in 
the activation of IRF family factors [36].
Thus, the interaction of the particular TLR with its 
ligand triggers a signaling cascade that leads to the ex-
pression of a specific gene pattern (cytokines, antimi-
crobial factors, etc.).
However, many details of the triggering of TLR-de-
pendent signaling and its downstream effects still re-
main unclear. To the best of our knowledge, there is no 
reported data characterizing the overall transcriptome 
and proteome alterations occurring in response to the 
activation of distinct TLRs.
Fig. 2.  
TLR-dependent 
signaling path-
ways.REVIEWS
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Table 3. Effect of TLRs on tumor growth and development.
Tumor-stimulating activity TLR Antitumor activity TLR
Stimulation of angiogenesis 2, 9 Suppression of angiogenesis 7, 9
Stimulation of proliferation 3, 4 Development of apoptosis 3, 4, 7, 9
Chemoresistance 4 Elevation of chemosensitivity 2, 4, 7
Activation of regulatory T-cells (Treg) 4, 5
Inhibition of Treg, antigen presentation 4, 5, 7, 8, 9
Cytotoxicity 9
TLRS AND TUMORS
Fundamentally different effects of TLRs on tumors 
have been reported to date. On one hand, TLRs (and 
their ligands) can suppress tumor growth, on the other 
hand, they can stimulate tumor progression and influ-
ence tumor resistance to chemotherapy. In order to ex-
plain these contradictory data, we shall consider both 
cases in detail.
ANTITUMOR ACTIVITY OF TLRS
Currently, many ТLR agonists are in clinical trials as 
antitumor agents (Table 2). Particularly, both natural 
(ssRNA) and synthetic (imiquimod) agonists of ТLR7 
and TLR8 have demonstrated high activity against 
chronic lymphocytic leukemia and tumors of the skin 
[37]. The TLR9 ligand CpG can suppress the growth of 
lymphomas and tumors of the brain, kidney, and skin 
[28]. The TLR3 ligand poly(IC) possesses a proapoptotic 
effect on both tumor and surrounding cells (for exam-
ple, endothelial cells) [38].
It has been reported that the ТLR4 agonists LPS 
from Gram-negative bacteria and OK-432 (picibanil; 
a lyophilized preparation of a low-virulence strain of 
Streptococcus pyogenes, inactivated by heating with 
penicillin G) possess high antitumor activity, when ad-
ministered intratumorally. However, both LPS and ОК-
432 could not suppress tumor growth upon systemic ad-
ministration [39]. At present, ОК-432 is being tested at 
the second stage of clinical trials as medication against 
colorectal and lung cancer. It has also been shown that 
OM-174, a chemical agonist of TLR2/4, can inhibit the 
progression of melanoma and increase the survival rate 
of animals in experiments when introduced together 
with cyclophosphamide [40]. These experiments have 
shown that TLR2/4 agonists induce the secretion of 
TNF-α and expression of inducible NO-synthase. NO 
is known to induce apoptosis in tumor cells resistant to 
chemotherapy, thus prolonging the lifespan of mice. 
Another known antitumor preparation of microbial 
genesis is BCG (Bacillus Calmette-Guérin), which ac-
tivates TLR-dependent reactions (TLR2, 4, 9). This 
preparation has been successfully used in the therapy 
of urinary bladder tumors for over 30 years [41].
Of note, various TLR agonists are presently in clini-
cal trials as potential medications against tumors of dif-
ferent geneses (Table 2).
One of the main mechanisms underlying the antitu-
mor activity of TLRs is their capability to activate the 
development of a tumor-specific immune response. The 
activation of TLRs
1) stimulates (directly or indirectly) the migration of 
NK-cells, cytotoxic T-cells, and type I T-helpers into the 
tumor, which causes the lysis of tumor cells via secretion 
of various effectors (perforin and IFN-γ) [42]; and
2) results in the secretion of type I IFNs (IFN-α, β) [43].
Another possible mechanism underlying the anti-
tumor effect of TLRs is the TLR-dependent transition 
of tumor-stimulating macrophages (M2 type) into the 
tumor-suppressing type M1. Type M2 macrophages are 
characterized by the expression of cytokines, such as 
TGF-β and IL-10 ---components required for tissue re-
pair and remodeling. TGF-β stimulates tumor cell prolif-
eration, while IL-10 directs the development of the im-
mune response to Th2, thus blocking the development of 
the cellular antitumor immune response. Alternatively, 
type M1 macrophages express IL-1, -6, -12, TNF-α, and 
IFN-γ, thereby  stimulating the development of the cel-
lular antitumor (Th1) immune response [44].
TUMOR-STIMULATING ACTIVITY OF TLRs
Chronic infections and inflammations are the most im-
portant factors known to stimulate the development of 
a malignant neoplasm. In particular, stomach cancer can 
be associated with a chronic inflammation induced by a 
pathogen; namely, Helicobacter pylori, and a chronic in-
flammation of the digestive tract is often associated with 
colorectal cancer [45]. Moreover, in some cases the use of 
nonsteroidal anti-inflammatory drugs can decrease the 
risk of malignant neoplasm development [46].
ТLRs are key players in the system of innate immu-
nity in animals, including humans; they participate in 
the mechanisms of inflammatory response when the 
cells come into contact with various pathogens. The role 
of TLRs in the development and progression of vari-26 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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ous tumors is being studied in detail currently. Several 
mechanisms have been proposed to explain ТLR impli-
cation in the stimulation of tumor formation and devel-
opment (Table 3).
NF-κB is one of the major factors that provide the 
interrelationship between chronic inflammation and 
tumor formation [47]. This factor is constitutively acti-
vated in more than 90% of human tumors, such as acute 
and chronic myeloid leukemia, prostate cancer, multi-
ple myeloma, hepatocarcinoma, etc. [48, 49]. In relation 
to this, the agents that are capable of activating NF-κB 
can be directly implicated in tumor development and 
progression. The interaction of pathogens with TLRs 
on the cell’s surface is known to result in the activa-
tion of NF-κB and expression of NF-κB –dependent 
genes, thus determining the participation of TLRs in 
the stimulation of carcinogenesis. The activation of NF-
κB leads to an increase in the level of IL-1, IL-2, IL-6, 
IL-10, and TNF-α cytokine production, migration of 
immune cells to the inflammation’s focus due to the in-
creased production of chemokines, “maintenance”of 
chronic inflammation, increase in the production of 
anti-apoptotic factors, etc. These indicated properties 
can promote tumor survival and progression due to the 
inhibition of apoptosis and cytotoxicity, and induction 
of angiogenesis [50].
An elevated level of TLRs has been reported in vari-
ous tumor cells, and the frequency of induced tumor 
formation is decreased in  TLR knockout mice [67]. 
Moreover, the increase in TLR expression on prostate 
cancer or head and neck tumor cell surfaces can stimu-
late their proliferation [51].
Huang and associates [31] have demonstrated that 
Listeria monocytogenes has a direct tumor-stimulating 
effect associated with its ability to activate the TLR2-
dependent signaling pathways in ovary cancer cells. 
Moreover, the TLR2-dependent activation of NF-κB 
caused by L. monocytogenes results in an enhanced re-
sistance of tumor cells to chemotherapeuticals [31]. The 
interrelationship between TLR2 and tumor progression 
has been confirmed in another independent study, in 
which Karin et al, [67] proved this receptor’s key role 
in lung cancer metastasis formation. Metastasis and 
progression of tumors are essentially retarded in TLR2 
knockout mice, compared with wild-type mice. The 
key role in lung cancer progression belongs to myeloid 
cells expressing TNF-α in response to their stimula-
tion by versican (proteoglycan of extracellular matrix, 
ligand for TLR2, the level of which is elevated in many 
tumor cell types). In our research, we also studied the 
role of TLR2 in tumor progression. In particular, infec-
tion with mycoplasma (Mycoplasma arginini) or the 
addition of its structural components (LAMP) to the 
cells expressing TLR2 resulted in the suppression of 
apoptosis and acceleration of tumor growth in vivo [52, 
53]. Thus, TLRs have a tumor-stimulating effect that is 
mediated by myeloid cells [54].
Similar data was obtained for TLR4, another member 
of the TLR family. Systemic (intravenous) injection of 
LPS (the ligand of this receptor) stimulated breast aden-
ocarcinoma cell migration, increased their invasion, and 
stimulated angiogenesis in tumors as well [30]. Similar 
results were obtained on another model – colorectal ad-
enocarcinoma; LPS increased the survival of tumor cells, 
stimulated their proliferation, and, when injected intra-
peritoneally, enhanced metastasis [55]. Moreover, Huang, 
et al.  have demonstrated that tumor cells expressing 
TLR4 cause a substantially more aggressive develop-
ment of  a disease, reducing the lifespan of mice in com-
parison with mice of isogenic line with TLR4 inactivated 
by specific siRNA. The obtained data has made possible 
the supposition that endogenous ligands (heat shock pro-
teins, β-defensines, and endogenous LPS thrown from 
the gut) can influence the progression of TLR4-positive 
tumors, partially akin to the tumor-stimulating effects 
of TLR2 and its endogenous ligand versican [56].
However, data illustrating the tumor-stimulating 
effect of TLRs have been obtained not only for TLR2 
and TLR4; elevated expression of TLR5 and TLR9 on 
the cervical epithelial cell’s surface can be associated 
with cervical cancer progression [57] as well. A high 
level of TLR9 expression was observed in clinical sam-
ples of lung cancer and tumor cell lines. In these cells, 
TLR9 stimulation by specific agonists resulted in in-
creased production of tumor-associated cytokines [58]. 
The TLR9 level is also elevated on the surface of hu-
man prostate cancer cells [59]. The treatment of such 
cells with the TLR9 ligands CpG-oligodeoxynucleotide 
(ODN-CpG) or bacterial DNA elevated the invasion 
of tumor cells. The elevation of tumor cell invasion via 
TLR9 activation can be regarded as a new mechanism 
by which chronic infections can stimulate prostate can-
cer cell growth.
However, not only various infectious agents and 
their structural components can stimulate carcinogen-
esis via interaction with the TLRs. DAMP, the nuclear 
and cytoplasmic proteins of necrotic cells, are known to 
serve as TRL ligands. DAMP released from damaged 
cells can be recognized by various TLRs on the surface 
of immune cells with subsequent activation of TLR-
dependent signals resulting in the suppression of the 
antitumor immune response and, as a consequence, in 
the stimulation of tumor progression [60].
The molecules that potentially possess a tumor stim-
ulating effect include heat shock proteins (HSP60, 70), 
ATP and uric acid, the Ca2+-modulating protein family 
(S100), the protein HMGB1 and nucleic acids, whose 
DNA-binding protein HMGB1 is the most well-studied. REVIEWS
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HMGB1 released from damaged cells activates the im-
mune system via interaction with TLRs. In cell cultures, 
HMGB1 was shown to stimulate melanoma, as well as 
breast, colon, pancreas, and prostate cancer cell growth. 
HMGB1 can activate TLR2 and TLR4 on the surface of 
tumor and immune cells and, as a result, induce tumor 
progression and metastasis [61].
Elevated expression of DAMP proteins, particularly 
S100 family members, is shown in melanoma cells; these 
proteins can stimulate the growth of melanoma cells 
and lymphocytes, peripheral blood lymphocytes, and 
act as an autocrine tumor growth factor. The S100A4 
protein, being a TLR ligand, stimulates the metastasis 
of breast cancer cells, and its elevated expression is an 
indicator of a poor prognosis. In spite of the interrela-
tionship between S100A4 and metastasis, the protein 
can be expressed in macrophages, lymphocytes, and 
fibroblasts. Recent studies have shown that the S100A8 
and S100A9 proteins produced by primary tumor can 
activate serum amyloid A (SAA) 3 in lung tissues, 
thereby creating conditions for the formation of a met-
astatic niche. SAA3 is a ligand for TLR4 on the surface 
of lung endothelial cells and macrophages. TLR4 acti-
vation facilitates the migration of tumor cells from the 
primary focus into the lung tissue via the creation of a 
microenvironment favorable to tumor growth. Thus, 
the suppression of the S100–TLR4-signaling pathway 
effectively counteracts the formation of metastasis in 
the lung [62].
In summing up the described effects, one can come 
to the conclusion that TLR can, on the one hand, di-
rectly or indirectly participate in tumor progression, 
and, on the other hand, increase tumor cell resistance 
to proapoptotic agents.
The data presented illustrate a complex mechanism 
showing the tumor-stimulating effect of TLRs and 
their ligands, which is to be studied in detail. However, 
despite the complexity of the issue, one can highlight 
some key points that determine the tumor stimulating 
effect of TLRs:
1) TLR interaction with its own ligands induces the 
activation of the NF-κB transcription factor and, as 
a consequence, an increase in the production of vari-
ous pro-inflammatory cytokines (IL-6, MCP-1, MIF, 
GRO-α, etc.), as well as a number of anti-apoptotic 
proteins, which facilitates a direct or indirect tumor-
stimulating effect;
2) TLR-dependent activation of myeloid cells and 
their progenitors is apparently the determining factor 
in the formation of metastasis. A series of independent 
works have demonstrated that myeloid cells migrat-
ing from the bone marrow (in response to endogenous 
stimulation) into tissues play a key role in the formation 
of metastasis niches [30, 54]. Since endogenous (versi-
can, fibronectin, etc.) and exogenous (microbial origin) 
TLR ligands are known to be capable of stimulating 
myeloid cells and their progenitors and increasing the 
metastatic potential of the tumor, it is very likely that 
an interrelationship exists between the TLR-depend-
ent activation of myeloid cells and their subsequent in-
volvement in metastasis;
3) TLR activation can stimulate angiogenesis via 
angiogenic factors, such as IL-8, vascular endothelial 
growth factor (VEGF), and matrix metalloproteinases 
(MMP), as well as enhance the adhesive and invasive 
activity of tumor cells, in line with the increase in the 
permeability of blood vessels.
TOLL-LIKE RECEPTORS IN TUMOR THERAPY
Antitumor therapy based on the delivery of TLR lig-
ands into the foci of tumor growth seems promising, 
because TLR agonists can induce an antitumor immune 
response by regulating the function in immune cells 
localized in the microenvironment of the tumor. The 
imiquimod containing the TLR7 agonist may represent 
an example of such therapy. This drug is used against 
actinic keratosis and basal cell carcinoma. The possi-
bility of using this drug as an adjuvant in the therapy 
of melanoma is also under study [63, 64]. Yet another 
TLR7 agonist, 852A, is used in tumor therapy. Pres-
ently, the possibility of using 852A against chronic 
lymphoid leukosis and other solid tumors is under con-
sideration [65]. ODN-CpG, a TLR9 agonist, induces the 
activation and maturation of dendrite cells and stimu-
lates the development of the T-cellular antitumor re-
sponse. Clinical trials of TLR9 agonists are presently 
under way in the context of their safety and efficacy 
in the therapy of breast, colorectal, and lung cancers, 
melanoma, glioblastoma, etc. [28]. Macrophage-acti-
vating lipopeptide-2 (MALP-2), a TLR2/6 agonist, has 
shown encouraging results in the therapy of pancre-
atic cancer; the intratumoral injection of MALP-2 with 
gemcitabine during laparotomia substantially increased 
the lifespan of patients with incompletely re-sectable 
cancer (from 9 to 17 months) [66]. The described exam-
ples demonstrating the effective use of TLR agonists in 
tumor therapy are evidence of their potential, as well 
as the reasonableness of further studies directed to-
ward the development of antitumor pharmaceuticals 
with a similar mechanism of action.
However, as mentioned above, many tumor cells 
can express TLRs on their surface, and the direct in-
teraction of these cells with TLR ligands can enhance 
the progression of the tumor and make it less sensitive 
to chemotherapy. Thus, it is likely that TLR agonists 
permanently circulating in an organism (pathogenic 
microorganisms that can overcome the immune bar-
rier; LPS of bacteria comprising normal gut microflora, 28 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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which can be thrown into the bloodstream; and own 
endigenous ligands) can directly or indirectly favor the 
advancement of tumor progression.
In this regard, a promising avenue for the therapy 
of malignant tumors is an approach directed toward 
the suppression of TLR-dependent signaling pathways. 
The employment of NF-κB inhibitors can be distin-
guished as a known approach that is already used in 
the therapy of malignant tumors.
The constitutive activation of NF-κB is observed in 
tumors, such as Hodgkin’s lymphoma (Hodgkin’s dis-
ease), acute lymphoblastic leucosis, multiple myeloma, 
breast, colon, lung, ovary, and prostate cancers, various 
lymphomas, liver cancer, and melanoma, amongst oth-
ers [48, 49].
The following pharmaceutical groups are used for 
the suppression of NF-κB activity: nonsteroidal anti-
inflammatory agents; substances-inhibiting IKK and 
COX-2 activities; natural and bioavailable inhibitors of 
IKKβ, such as flavonoids, prostaglandins, BMS-345541, 
PS1145, SC-514, and SPC839; as well as proteasome 
inhibitors that inhibit  NF-κB activity by preventing 
IkB degradation, such as bortezomib (PS-341), irinote-
kan, gemcitabine, and other drugs widely used in the 
therapy of tumors of the colon, small intestine, stom-
ach, pancreas, etc. [67].
Since NF-κB is a key component of the TLR-depend-
ent signaling pathway, the use of its inhibitors seems 
promising for the suppression of TLR-dependent stim-
ulation of tumor growth.
In our opinion, other promising targets are TLRs 
themselves. Since TLR2 and TLR4 (receptors implicat-
ed in the stimulation of tumor growth) are expressed 
on the cell’s surface, specific molecules (antibodies, 
chemical inhibitors) suppressing their functional activ-
ity seem usable. Antibodies that inhibit TLR activities 
are currently available; however, data on their clinical 
use have not been reported yet.
CONCLUSION
ТLRs are members of the PRR family. The actions asso-
ciated with their activation go beyond reactions of the 
innate immune response. Participation in dendritic cell 
activation, regulation of specific T- and B-cellular im-
mune responses, elevation of IFN expression, etc., pro-
vide for the TLR’s implication both in the development 
of effective innate and adaptive immune reactions in 
response to the penetration of various pathogens into 
the organism, and in supporting tissue homeostasis. The 
reported data in abundant research is evidence that 
it is possible to use TLR ligands as adjuvants for the 
immune therapy of malignant neoplasms. It is known, 
however, that TLR activation on the surface of tumor 
cells can result in enhanced progression of tumors of 
various origins.
Such a difference in effects primarily depends on 
the ligand type. As shown in Table 1, TLR can be di-
vided into two groups: inducing and noninducing IFN 
production. As a rule, the addition of TLR3, 4, 7, 8, and 
9 agonists that activate IRE considerably suppresses 
tumor growth. However, there is currently no data in-
dicating any anti-tumor effect of the agonists of TLR2, 
which, unlike the listed receptors (TLR3, 4, 7, 8, 9), 
cannot activate the production of IFN type I. The way 
they are introduced is yet another feature leading to 
differences in the effects of TLR agonists on tumors. 
Intratumoral introduction of TLR3, 4, 7, 8, 9 ligands in-
duces tumor cell death and, in most cases, a decrease 
in the tumor’s size. The most probable explanation for 
the anti-tumor activity of these TLRs is their capabil-
ity to (A) induce local expression of IFN types I and II, 
which are known to induce tumor cells death, and (B) 
activating cell immunity in response to the interaction 
with ligand. The death of tumor cells, their phagocy-
tosis, and subsequent presentation of tumor-specific 
antigens cause additional stimulation of specific anti-
tumor immunity. However, a series of works [30, 55, 
56] have demonstrated that a systemic introduction of 
TLR4 ligands is often associated with the stimulation of 
tumor growth. In our opinion, this difference is related 
to the fact that intratumoral injection of TLR4 ligand 
(LPS), compared with its systemic introduction, results 
in substantially higher IFN accumulation directly in 
the tumor. Since IFNs are short-distance effector pro-
teins acting at sufficiently high concentrations, their 
production outside the tumor (at systemic introduction) 
does not result in tumor cell death and, hence, in the 
development of anti-tumor immunity. Inflammatory 
cytokines and chemokines can play a dual role after a 
local or systemic introduction of LPS: they either favor 
the development of anti-tumor immunity after intra-
tumoral injection of LPS, or positively influence the 
growth of the tumor, resistance of its cells, and metas-
tasis potential after the systemic introduction of LPS in 
the absence of targets for the immune system.
Thus, the available data suggest that TLR agonists 
have a dual effect on tumor growth. This dual TLR ef-
fect is indicative of the more complex functional role 
of TLRs in tumor biology. Such a role by TLRs is obvi-
ously beyond the frame of a simple NF-κB activation. 
The influence of various TLR ligands on tumors must 
be studied taking into account multiple factors, includ-
ing the TLR expression level, type of tissue from which 
the tumor originates, the tumor’s microenvironment, 
and many others. The systemic study of TLR’s role and 
functions in tumor cells can contribute substantially to 
the development of new antitumor pharmaceuticals 
with a TLR-dependent mechanism of activity. REVIEWS
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